Telix Pharmaceuticals (TLPPF) Expected to Announce Quarterly Earnings on Thursday

Telix Pharmaceuticals (OTCMKTS:TLPPF) is anticipated to post its results before the market opens on Thursday, August 20th. Analysts expect Telix Pharmaceuticals to announce earnings of $0.0447 per share and revenue of $479.6290 million for the quarter.

Telix Pharmaceuticals Stock Down 3.0%

TLPPF stock opened at $11.15 on Wednesday. Telix Pharmaceuticals has a twelve month low of $5.91 and a twelve month high of $12.50. The stock has a 50-day simple moving average of $10.57 and a two-hundred day simple moving average of $9.40.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.00.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.